SCHEMBL316481

SCHEMBL316481

[CH](c1ccccc1)C1CCCC1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
MAOB P27338 1/20 0.42
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
G6PC1 P35575 1/20 0.39
HSP90AA1 P07900 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1119493 0.98 POLB (0.44) POLBGAAMAOBMAPTHPGD
SCHEMBL1119454 0.98 POLB (0.44) POLBGAAMAOBMAPTHPGD
SCHEMBL217659 0.98 POLB (0.44) POLBGAAMAOBMAPTHPGD
SCHEMBL1119433 0.95 ALDH1A1 (0.42) POLBGAAMAOBMAPTSMN1; SMN2
SCHEMBL674275 0.90 MAOB (0.46) POLBGAAMAOBMAPTSMN1; SMN2
SCHEMBL6002937 0.79 SLC18A3 (0.48) MAOB
SCHEMBL6949622 0.78 TLR4 (0.45) POLBMAOBMAPT
SCHEMBL10681390 0.78 KDM1A (0.40) MAOB
SCHEMBL24198614 0.76 MAOA (0.53) MAOB
SCHEMBL652509 0.76 NPC1 (0.42) MAOBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273226-B2 Pyrazolyl-heteroarylamides as pesticides BAYER ANIMAL HEALTH GMBH (DE) 2019-04-30 US claimed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 CN claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
US-6376548-B1 FUNGICIDES; HERBICIDES; INSECTICIDES ROHM AND HAAS COMPANY 2002-04-23 US claimed
EP-0680469-B1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME BOEHRINGER INGELHEIM PHARMA (DE) 2000-04-26 EP claimed
US-5658943-A VASODILATOR FOR CARDIOVASCULAR DISORDER, HYPOTENSIVE AGENT WARNER-LAMBERT COMPANY (US) 1997-08-19 US claimed
JP-H08505862-A 1996-06-25 JP claimed
EP-0680469-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME Dr. Karl Thomae GmbH (DE) 1995-11-08 EP claimed
WO-1994017035-A1 AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME DR. KARL THOMAE GMBH (DE) 1994-08-04 WO claimed
US-5234942-A Treating allergic pulmonary disorders, asthma ICI AMERICAS INC. (US) 1993-08-10 US claimed
US-4997844-A Compounds for the treatment of allergic or inflammatory diseases or shock conditions ICI AMERICAS INC. (US) 1991-03-05 US claimed
EP-0179619-B1 HETEROCYCLIC AMIDES ICI AMERICAS INC. (US) 1990-09-05 EP claimed
CN-85108623-A Preparation has the novel method of the heterocycleamide of medical active 1986-07-30 CN claimed
EP-0179619-A1 Heterocyclic amides ICI AMERICAS INC. (US) 1986-04-30 EP claimed
US-3971804-A ACARICIDES, FUNGICIDES, INSECTICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-07-27 US claimed
CN-118331005-A Electrophotographic photoreceptor, process cartridge, and image forming apparatus 富士胶片商业创新有限公司 2024-07-12 CN disclosed
CN-85108623-A Preparation has the novel method of the heterocycleamide of medical active 1986-07-30 CN disclosed
EP-0179619-A1 Heterocyclic amides ICI AMERICAS INC. (US) 1986-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273226-B2 Pyrazolyl-heteroarylamides as pesticides CYP4Z1, NAT1, CYP4F3 POLB 4381/4885GAA 2832/4885MAOB 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.